TraceLink breaks new record for highest quarterly sales bookings in Q2 2017
Company also becomes the first solution provider to achieve 100 pharmaceutical and contract manufacturers live and ready for serialization.
TraceLink has announced financial and company results for the second quarter of 2017.
Growth highlights for the second quarter of 2017 include
- 42% representing pharmaceutical and contract manufacturers
- 7% representing wholesale distributors
- 51% representing pharmacies, hospitals and health systems, covering more than 4,200 US dispensing locations.
“I am extremely proud of our global team for achieving our highest new quarterly sales bookings ever, hitting an all-time record for the company,” said Shabbir Dahod, president and CEO, TraceLink. “Since track and trace regulatory deadlines were enacted, TraceLink has experienced explosive year-over-year growth, validating the industry’s need for a proven, scalable network to meet their serialization needs. As the industry integrates serialization into day-to-day operations, the TraceLink network is the only solution capable of providing critical value-add services that leverage the sharing of real-time information for business insights that will improve patient outcomes.”
Additional Q2 2017 growth highlights and milestones include
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance